Galderma

Galderma has received approval in China for Relfydess for the temporary treatment of moderate to severe glabellar lines between the eyebrows. The ready-to-use, liquid neuromodulator formulation supported approval with a local phase III study and global Ready studies involving more than 2,300 participants. In Ready‑1, 82.9% of patients showed marked improvement after one month versus 0% in the placebo group; 39% improved on day one and effects lasted up to six months in as many as 75% of patients. Relfydess is considered safe; adverse events were rare and included local reactions, headache and transient eyelid drooping. The product is now approved in more than 35 markets. » Más en finanzen.net

At the Aesthetic & Anti-Aging Medicine World Congress in Dubai, Galderma is presenting eight abstracts, a symposium and six meet-the-expert sessions on Relfydess, Sculptra and Restylane. The presented data show expanded applications for Sculptra and Restylane in facial and body treatments as well as high efficacy and patient satisfaction. » Más en finanzen.net

Galderma is buying the US brand ZO Skin Health for $1.5 billion in cash, financed from cash on hand and bank loans. The transaction is expected to close in late 2026 or early 2027 and is anticipated to be neutral to adjusted earnings per share in the first full fiscal year. For 2027 Galderma expects a slight dilution of the adjusted EBITDA margin, with the margin expected to roughly align with the group average again from 2028. ZO complements the existing portfolio, which includes brands such as Cetaphil and Alastin, and strengthens Galderma’s position in the physician-dispensed medical skincare market. » Más en finanzen.net